# Nuclide record sstr-theranostics-roadmap (roadmap). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/roadmaps/sstr-theranostics-roadmap/>
  a schema:CreativeWork ;
  nuclide:kind "roadmap" ;
  schema:identifier "sstr-theranostics-roadmap" ;
  schema:name "SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha"@en ;
  schema:description "Neuroendocrine tumours were the proving ground for the whole idea of theranostics: find a receptor on the tumour, image it with a low-dose radioactive scan, then treat with a matched higher-dose version of the same molecule. That sequence took thirty years to build and is now being extended with more powerful alpha-particle versions."@en ;
  schema:url <https://nuclide.cc/roadmaps/sstr-theranostics-roadmap/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000Approv.pdf>, <https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets>, <https://www.novartis.com/us-en/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors>, <https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053> ;
  nuclide:related <https://nuclide.cc/isotopes/ga-68/>, <https://nuclide.cc/isotopes/in-111/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/>, <https://nuclide.cc/isotopes/pb-212/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/>, <https://nuclide.cc/indications/meningioma/> ;
  nuclide:technologies <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/targeted-alpha-therapy/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/ryz101/>, <https://nuclide.cc/drugs/alphamedix/>, <https://nuclide.cc/drugs/itm-11/> ;
  nuclide:trials <https://nuclide.cc/trials/netter-1/>, <https://nuclide.cc/trials/action-1/>, <https://nuclide.cc/trials/alphamedix-02/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-netter-1-nejm-2017/>, <https://nuclide.cc/key-papers/paper-netter-2-lancet-2024/> .